Department of Surgery, Keio University School of Medicine, Tokyo, Japan.
Department of Preventive Medicine and Public Health, Keio University School of Medicine, Tokyo, Japan.
J Gastrointest Surg. 2023 Nov;27(11):2515-2525. doi: 10.1007/s11605-023-05836-0. Epub 2023 Sep 22.
It is unclear how early- and delayed-onset organ/space surgical site infections (SSIs) affect the long-term prognosis of patients with colorectal cancer, who are potential candidates for adjuvant chemotherapy. This study aimed to investigate the association between the timing of SSI onset and clinical outcome.
This retrospective, multicenter cohort study evaluated patients who were diagnosed with high-risk stage II or III colorectal cancer and underwent elective surgery between 2010 and 2020. Five-year recurrence-free survival (RFS) was the primary endpoint and was compared between early SSI, delayed SSI (divided based on the median date of SSI onset), and non-SSI groups.
A total of 2,065 patients were included. Organ/space SSI was diagnosed in 91 patients (4.4%), with a median onset of 6 days after surgery. The early-onset SSI group had a higher proportion of patients with Clavien-Dindo grade ≥IIIb SSI than the delayed-onset SSI. Patients who received adjuvant chemotherapy (AC) had earlier organ/space SSI onset than those who did not. The adjusted hazard ratio of 5-year RFS in the delayed-onset SSI was 2.58 (95% confidence interval: 1.43-4.65; p = 0.002): higher than that in the early-onset SSI, with the non-SSI as the reference.
Delayed-onset organ/space SSI worsened long-term prognosis compared to early-onset, and this may be due to delayed initiation of AC. Patients who are clinically suspected of having lymph node metastasis might need additional intervention to prevent delays in commencing AC due to the delayed SSI.
目前尚不清楚早发性和迟发性器官/腔隙外科部位感染(SSI)如何影响结直肠癌患者的长期预后,这些患者可能是辅助化疗的潜在候选者。本研究旨在探讨 SSI 发病时间与临床结果之间的关系。
本回顾性多中心队列研究评估了 2010 年至 2020 年间诊断为高危 II 期或 III 期结直肠癌并接受择期手术的患者。无复发生存期(RFS)为主要终点,并在早发性 SSI、迟发性 SSI(根据 SSI 发病的中位数日期进行划分)和非 SSI 组之间进行比较。
共纳入 2065 例患者。91 例(4.4%)患者诊断为器官/腔隙 SSI,术后中位发病时间为 6 天。早发性 SSI 组中 Clavien-Dindo 分级≥IIIb 的 SSI 患者比例高于迟发性 SSI 组。接受辅助化疗(AC)的患者 SSI 发病时间早于未接受 AC 的患者。调整后的迟发性 SSI 5 年 RFS 风险比为 2.58(95%置信区间:1.43-4.65;p = 0.002):高于早发性 SSI,以非 SSI 为参照。
与早发性 SSI 相比,迟发性器官/腔隙 SSI 恶化了长期预后,这可能是由于 AC 延迟启动。临床上怀疑有淋巴结转移的患者可能需要额外的干预措施,以防止因迟发性 SSI 而延迟开始 AC。